Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells
Taniai, Makiko , Grambihler, Annette, Higuchi, Hajime, Werneburg, Nate, Bronk, Steve F., Farrugia, Daniel J., Kaufmann, Scott H. , Gores, Gregory J.

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 10 | Pages: 3517-3524

10.1158/0008-5472.can-03-2770 | PMID 15150106 Get It

AbstractCholangiocarcinomas are usually fatal neoplasms originating from bile duct epithelia. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent for cancer therapy, including cholangiocarcinoma. However, many cholangiocarcinoma cells are resistant to TRAIL-mediated apoptosis. Thus, our aim was to examine the intracellular mechanisms responsible for TRAIL resistance in human cholangiocarcinoma cell lines. Three TRAIL-resistant human cholangiocarcinoma cell lines were identified. All of the cell lines expressed TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4) and TRAIL-R2/DR5. Expression of TRAIL decoy receptors and the antiapoptotic cellular FLICE-inhibitory protein (cFLIP) was inconsistent across the cell lines. Of the antiapoptotic Bcl-2 family of proteins profiled (Bcl-2, Bcl-xL, and Mcl-1), Mcl-1 was uniquely overexpressed by the cell lines. When small-interfering-RNA (siRNA) technology was used to knock down expression of Bcl-2, Bcl-xL, and Mcl-1, only the Mcl-1-siRNA sensitized the cells to TRAIL-mediated apoptosis. In a cell line stably transfected with Mcl-1-small-hairpin-RNA (Mcl-1-shRNA), Mcl-1 depletion sensitized cells to TRAIL-mediated apoptosis despite Bcl-2 expression. TRAIL-mediated apoptosis in the stably transfected cells was associated with mitochondrial depolarization, Bax activation, cytochrome c release from mitochondria, and caspase activation. Finally, flavopiridol, an anticancer drug that rapidly down-regulates Mcl-1, also sensitized cells to TRAIL cytotoxicity. In conclusion, these studies not only demonstrate that Mcl-1 mediates TRAIL resistance in cholangiocarcinoma cells by blocking the mitochondrial pathway of cell death but also identify two strategies for circumventing this resistance.
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer
Meyerhardt, Jeffrey A. , Sloan, Jeffrey A., Sargent, Daniel J. , Goldberg, Richard M. , Pollak, Michaël , Morton, Roscoe F., Ramanathan, Ramesh K., Williamson, Stephen K. , Findlay, B., Fuchs, Charles S. , Sargent, Daniel J , Williamson, Stephen , Pollak, Michael N , Meyerhardt, Jeffrey A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 6 | Pages: 1402-1410

10.1158/1055-9965.epi-04-0862 | PMID 15941948 Get It

Abstract Objective: Predictors of quality of life (QOL) in patients with metastatic colorectal cancer are lacking. The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer. Method: We used a cohort of 526 patients with metastatic colorectal cancer treated with combination chemotherapy. Plasma samples of IGF-I, IGF-II, IGF binding protein-3, and C-peptide were collected before initiation of chemotherapy. QOL was measured by the uniscale instrument and the Symptom Distress Scale at baseline and throughout treatment. Results: Baseline plasma levels of IGF-I and IGF-II before initiation of chemotherapy were significantly associated with several important baseline QOL measures in patients with metastatic colorectal cancer. Patients with lower levels of IGF-I reported increased distress with regard to appearance, appetite, cough, and nausea intensity after adjustment for potential confounders. Similarly, decreased levels of IGF-II were predictive of worse quality related to appearance, appetite, fatigue, nausea frequency and intensity, pain frequency, and composite Symptom Distress Scale score. IGF binding protein-3 and C-peptide were not predictive of baseline QOL. Baseline biomarkers were not associated with subsequent changes in QOL during treatment. Higher body mass index was significantly associated with superior baseline QOL in several areas; nonetheless, the association of IGF-I and IGF-II with baseline QOL measures remained significant even after controlling for baseline body mass index. Conclusion: Baseline plasma IGF-I and IGF-II are significantly associated with symptom distress. Whether this association is simply reflective of patient nutritional status and/or disease burden or represents an independent biological effect of IGFs on QOL remains uncertain. Nonetheless, these data suggest that molecular biomarkers may be useful predictors of QOL in cancer patients.
Genetically Characterized Positive Control Cell Lines Derived from Residual Clinical Blood Samples
Bernacki, Susan H. , Beck, Jeanne C., Stanković, Ana , Williams, Laurina O. , Amos, Jean, Snow-Bailey, Karen, Farkas, Daniel H., Friez, Michael J., Hantash, Feras, Matteson, Karla J., Monaghan, Kristin G. , Muralidharan, Kasinathan, Pratt, Victoria M. , Prior, Thomas W., Richie, Kristy L., Levin, Barbara C., Rohlfs, Elizabeth M., Schaefer, Frederick V., Shrimpton, Antony E., Spector, Elaine , Stolle, Catherine A., Strom, Charles M. , Thibodeau, Stephen N. , Cole, Eugene C., Goodman, Barbara K. , Stenzel, Timothy T.

Mayo Clinic

Clinical Chemistry | September 16, 2005 | Volume: 51 | Issue: 11 | Pages: 2013-2024

10.1373/clinchem.2005.048694 | PMID 16166172 Get It

AbstractBackground: Positive control materials for clinical diagnostic molecular genetic testing are in critically short supply. High-quality DNA that closely resembles DNA isolated from patient specimens can be obtained from Epstein–Barr virus (EBV)–transformed peripheral blood lymphocyte cell lines. Here we report the development of a process to (a) recover residual blood samples with clinically important mutations detected during routine medical care, (b) select samples likely to provide viable lymphocytes for EBV transformation, (c) establish stable cell lines and confirm the reported mutation(s), and (d) validate the cell lines for use as positive controls in clinical molecular genetic testing applications.Methods: A network of 32 genetic testing laboratories was established to obtain anonymous, residual clinical samples for transformation and to validate resulting cell lines for use as positive controls. Three panel meetings with experts in molecular genetic testing were held to evaluate results and formulate a process that could function in the context of current common practices in molecular diagnostic testing.Results: Thirteen laboratories submitted a total of 113 residual clinical blood samples with mutations for 14 genetic disorders. Forty-one EBV-transformed cell lines were established. Thirty-five individual point and deletion mutations were shown to be stable after 20 population doublings in culture. Thirty-three cell lines were characterized for specific mutations and validated for use as positive controls in clinical diagnostic applications.Conclusions: A process for producing and validating positive control cell lines from residual clinical blood samples has been developed. Sustainable implementation of the process could help alleviate the current shortage of positive control materials.
A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk
Narla, Goutham , DiFeo, Analisa , Reeves, Helen L. , Schaid, Daniel J. , Hirshfeld, Jennifer, Hod, Eldad A. , Katz, Amanda, Isaacs, William B., Hebbring, Scott J. , Komiya, Akira , McDonnell, Shannon K. , Wiley, Kathleen E. , Jacobsen, Steven J. , Isaacs, Sarah D., Walsh, Patrick C., Chang, Bao-Li, Friedrichsen, Danielle M., Stanford, Janet L. , Ostrander, Elaine A. , Chinnaiyan, Arul M., Rubin, Mark A. , Xu, Jianfeng , Thibodeau, Stephen N. , Martignetti, John A., Karyadi, Danielle M. , Zheng, Shusen , Chang, Bao‐Li, Friedman, Scott L. , DiFeo, Analisa , Rubin, Mark A , McDonnell, Shannon K

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 4 | Pages: 1213-1222

10.1158/0008-5472.can-04-4249 | PMID 15735005 Get It

Abstract Prostate cancer is a leading and increasingly prevalent cause of cancer death in men. Whereas family history of disease is one of the strongest prostate cancer risk factors and suggests a hereditary component, the predisposing genetic factors remain unknown. We first showed that KLF6 is a tumor suppressor somatically inactivated in prostate cancer and since then, its functional loss has been further established in prostate cancer cell lines and other human cancers. Wild-type KLF6, but not patient-derived mutants, suppresses cell growth through p53-independent transactivation of p21. Here we show that a germline KLF6 single nucleotide polymorphism, confirmed in a tri-institutional study of 3,411 men, is significantly associated with an increased relative risk of prostate cancer in men, regardless of family history of disease. This prostate cancer–associated allele generates a novel functional SRp40 DNA binding site and increases transcription of three alternatively spliced KLF6 isoforms. The KLF6 variant proteins KLF6-SV1 and KLF6-SV2 are mislocalized to the cytoplasm, antagonize wtKLF6 function, leading to decreased p21 expression and increased cell growth, and are up-regulated in tumor versus normal prostatic tissue. Thus, these results are the first to identify a novel mechanism of self-encoded tumor suppressor gene inactivation and link a relatively common single nucleotide polymorphism to both regulation of alternative splicing and an increased risk in a major human cancer.
Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells
Ougolkov, Andrei V., Fernández-Zapico, Martín E. , Savoy, Doris N., Billadeau, Daniel D. , Ugolkov, Andrey , Urrutia, Raúl

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 6 | Pages: 2076-2081

10.1158/0008-5472.can-04-3642 | PMID 15781615 Get It

Abstract Recent studies using glycogen synthase kinase-3β (GSK-3β)–deficient mouse embryonic fibroblasts suggest that GSK-3β positively regulates nuclear factor κB (NFκB)–mediated gene transcription. Because NFκB is suggested to participate in cell proliferation and survival pathways in pancreatic cancer, we investigated the role of GSK-3β in regulating these cellular processes. Herein, we show that pancreatic cancer cells contain a pool of active GSK-3β and that pharmacologic inhibition of GSK-3 kinase activity using small molecule inhibitors or genetic depletion of GSK-3β by RNA interference leads to decreased cancer cell proliferation and survival. Mechanistically, we show that GSK-3β influences NFκB-mediated gene transcription at a point distal to the Iκ kinase complex, as only ectopic expression of the NFκB subunits p65/p50, but not an Iκ kinase β constitutively active mutant, could rescue the decreased cellular proliferation and survival associated with GSK-3β inhibition. Taken together, our results simultaneously identify a previously unrecognized role for GSK-3β in cancer cell survival and proliferation and suggest GSK-3β as a potential therapeutic target in the treatment of pancreatic cancer.
Completion pancreatectomy following pancreaticoduodenectomy: Clinical experience
Smith, C. Daniel , Sarr, Michael G., vanHeerden, Jon A.

Mayo Clinic

World Journal of Surgery | September 13, 2005 | Volume: 16 | Issue: 3 | Pages: 521-524

10.1007/bf02104459 | PMID 1350387 Get It

AbstractWhile pancreaticoduodenectomy is today performed with an operative mortality of <5%, the incidence of significant operative morbidity remains at least 25%. Albeit rarely, completion pancreatectomy during the early postoperative period may be required to manage uncontrolled pancreatic anastomotic leaks. From 1964 to 1988, pancreaticoduodenectomy was performed on 479 patients at our institution, 178 (37%) of whom required re‐operation in the early postoperative period. Of these, 11 (6%) patients underwent completion pancreatectomy at a mean interval of 18 days following Whipple resection. The indications prompting re‐operation included a suspected pancreatic leak (n=8), intra‐abdominal hemorrhage (n=2), and pancreaticocutaneous fistula (n=1). Operative findings necessitating completion pancreatectomy included pancreatic anastomotic dehiscence with severe surrounding inflammation/necrosis prohibiting reanastomosis or repair (n=10) and necrotizing pancreatitis with uncontrolled hemorrhage (1). Seven (64%) of these 11 patients died postoperatively of sepsis and multiple organ failure. The mean hospital stay in the 4 surviving patients was 46 days (range, 26 to 53 days). These 4 patients survived for a mean period of 24 months following hospital dismissal.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Cynthia, X. , Thomas, Sachdev , Mandrekar, Sumithra J. , Nikcevich, Daniel A., Rowland, Kendrith M. , Fitch, Tom R., Windschitl, Harold E., Hillman, Shauna L., Schild, Steven E. , Jett, James R., Obasaju, Coleman K., Adjei, Alex A. , Nair, Suresh , Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | August 31, 2005 | Volume: 23 | Issue: 25 | Pages: 5929-5937

10.1200/jco.2005.13.953 | PMID 16135464 Get It

Purpose A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non–small-cell lung cancer. Patients and Methods Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. Results One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. Conclusion Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated.
[O2‐03‐01]: Environmental enrichment mitigates cognitive deficits in APP/PS1 transgenic mice
Melnikova, Tatiana , Fadale, Daniel J., Xu, Guilian , Slunt, Hilda H., Gonzales, Victoria, Younkin, Linda H., Younkin, Steven G., Borchelt, David , Savonenko, Alena , Jankowsky, Joanna L.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.342 Get It

[O1‐01‐06]: Correlations between cholesterol‐related genetic risk scores and lower brain‐imaging measurements of regional glucose metabolism
Reiman, Eric M. , Caselli, Richard J. , Bandy, Daniel, Alexander, Gene E. , Stephan, Dietrich A. , Chen, Kewei , Lee, Wendy , Papassotiropoulos, Andreas

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.281 Get It

Regulation of RelB Expression during the Initiation of Dendritic Cell Differentiation
Cejas, Pedro J. , Carlson, Louise, Kolonias, Despina S. , Lindner, Inna, Billadeau, Daniel D. , Boise, Lawrence , Lee, Kelvin P. , Zhang, Jian , Boise, Lawrence H

Mayo Clinic

Molecular and Cellular Biology | August 17, 2005 | Volume: 25 | Issue: 17 | Pages: 7900-7916

10.1128/mcb.25.17.7900-7916.2005 | PMID 16107733 Get It